Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
May 19 2023 - 7:25AM
Alterity Therapeutics, a biotechnology company dedicated to
developing disease modifying treatments for neurodegenerative
diseases, today announced that David Stamler, M.D., Chief Executive
Officer of Alterity will present at the SHARE Series Monday
Management Update on Monday, May 22, 2023, at 11:00 am ET or 1:00am
AEST Tuesday, May 23, 2023.
This event is set in a fireside chat format and
intended for retail and institutional investors. Investors will
have the opportunity to ask questions during the chat.
A link to the live and archived webcast may be
accessed on the Alterity website under the Investors section Events
and Presentations, or directly at
https://www.openexchange.tv/share-series. An archived replay will
be available for approximately 90 days following the event.
About Alterity Therapeutics
Limited
Alterity Therapeutics is a clinical stage
biotechnology company dedicated to creating an alternate future for
people living with neurodegenerative diseases. The Company’s
lead asset, ATH434, has the potential to treat various Parkinsonian
disorders. Alterity also has a broad drug discovery platform
generating patentable chemical compounds to intercede in disease
processes. The Company is based in Melbourne, Australia, and San
Francisco, California, USA. For further information please visit
the Company’s web site at www.alteritytherapeutics.com.
Investor and Media Contacts:
AustraliaHannah
Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648
064
U.S.Remy Bernardaremy.bernarda@iradvisory.com
+1 (415) 203-6386
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Sep 2023 to Sep 2024